Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences

  Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences

BIO CEO & Investor Conference 2014 Leerink Global Healthcare Conference 2014

Business Wire

NEW YORK -- February 3, 2014

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief
Executive Officer, Gary S. Jacob, Ph.D., will present an overview of the
company at two February investment conferences being held at the Waldorf
Astoria in New York, N.Y.

Synergy is scheduled to present at the BIO CEO & Investor Conference on
Monday, February 10^th at 11:00am (EST), and at Leerink Global Healthcare
Conference on Thursday, February 13^th at 1:00pm (EST).

A live webcast of both presentations will be accessible through the Investor
Relations section of the company’s website at A replay
of the webcasts will be available on Synergy’s website for 60 days.

About Synergy

Synergy Pharmaceuticals Inc. is a biotechnology company focused on the
research and development of novel drugs for the treatment of gastrointestinal
(GI) diseases and disorders. Synergy has discovered proprietary analogs of the
human GI hormone, uroguanylin, the natural agonist for the intestinal
guanylate cyclase-C (GC-C) receptor. Both Synergy’s lead GC-C agonist,
plecanatide, and next-generation GC-C agonist, SP-333, mimic uroguanylin’s
natural functions by binding to and activating the GC-C receptor in the GI
tract to stimulate fluid and transit required for normal digestion.
Plecanatide is in phase 3 clinical trials for chronic idiopathic constipation
and a phase 2b study for irritable bowel syndrome with constipation. SP-333 is
in phase 2 development for opioid-induced constipation and is also being
explored for ulcerative colitis. For more information please visit


Synergy Pharmaceuticals Inc.
Media Contact:
Gem Gokmen
Office: 212-584-7610
Mobile: 646-637-3208
Investor Contact:
Bernard Denoyer
Office: 212-297-0020
Mobile: 203-300-8147
Press spacebar to pause and continue. Press esc to stop.